Moderna to Report Q4 Earnings: Is a Beat in Store for the Stock?

Key Takeaways Moderna is expected to beat Q4 estimates, with sales projected at $661.4M and a loss of $2.60 per share.COVID-19 vaccines are expected to drive most sales, while the RSV vaccine mResvia faces tough competition.Investors await updates on intismeran studies and FDA resubmission plans for the COVID-flu combo vaccine.We expect Moderna (MRNA) to surpass expectations when it reports fourth-quarter and full-year 2025 results on Feb. 13, before the opening bell. The company’s earnings beat estimates b ...